---
title: 'The role of the pathologist in the design and conducting of biomarker-driven
  clinical trials in cancer: position paper of the European Society of Pathology'
date: '2024-12-17'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39690330/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20241218172038&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: Clinical trials in oncology are important tools to identify and establish
  new effective drugs for cancer treatment. Since the development of the concept of
  precision oncology, a huge number of multi-centric biomarker-driven clinical trials
  have been performed and promoted by either academic institutions or pharmaceutical
  companies. In this scenario, the role of pathologists is essential in multiple aspects,
  with new challenges that should be addressed. In this position paper of the ...
disable_comments: true
---
Clinical trials in oncology are important tools to identify and establish new effective drugs for cancer treatment. Since the development of the concept of precision oncology, a huge number of multi-centric biomarker-driven clinical trials have been performed and promoted by either academic institutions or pharmaceutical companies. In this scenario, the role of pathologists is essential in multiple aspects, with new challenges that should be addressed. In this position paper of the ...